María Rodrigo-García

Hospital Universitario de La Princesa

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Adrián Peláez

HM Hospitales

Julio Ancochea

Hospital Universitario de La Princesa

Joan B. Soriano

Universidad Autónoma de Madrid

Rosa Girόn

Hospital Universitario de La Princesa

Ana Sofía Martín Hernández

Hospital Universitario de La Princesa

EÁ

Elena Ávalos

Hospital Universitario de La Princesa

Esteve Fernández

Institut Català d'Oncologia

José María Eiros Bachiller

Hospital Universitario de La Princesa

Rosa Mar Gómez Punter

Hospital Universitario de La Princesa

Marta García‐Clemente

Central University Hospital of Asturias

Cooperative Institutions

Hospital Universitario de La Princesa

Universidad Autónoma de Madrid

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias

Instituto de Salud Carlos III

Clinica de Pneumologie Iaşi

Spanish National Centre for Cardiovascular Research

Centro de Investigación Biomédica en Red

Roche (Spain)

Institut Català d'Oncologia

Institut d'Investigació Biomédica de Bellvitge

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Evolution of Lung Function in Pregnant Women With Cystic Fibrosis

Archivos de Bronconeumología (2023)

Ana Sofía Martín Hernández María Rodrigo-García Adrián Peláez Rosa Mar Gómez Punter Julio Ancochea

10.1016/j.arbres.2023.07.011

Cite

Citations (0)

Trends in mortality in Spain, with a special focus on respiratory-related conditions in the midst of the COVID-19 pandemic

Medicina Clínica (2024)

Adrián Peláez Joan B. Soriano María Rodrigo-García José L. Peñalvo Julio Ancochea

Pandemic

2019-20 coronavirus outbreak

10.1016/j.medcli.2024.08.004

Cite

Citations (0)

Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis Patients

Research Square (Research Square) (2024)

Marta Solís García Adrián Peláez Rosa Mar Gómez Punter M. López Claudia Madrid Carbajal

Abstract Background. This study aimed to assess how Elexacaftor/Tezacaftor/Ivacaftor (ETI) influences lung function, BMI, sweet test and mental health of Cystic Fibrosis (CF) patients, emphasizing on depression and anxiety. Methods. We conducted an observational, prospective, multicentre study including 108 patients over 18 years old who initiated ETI therapy between December 2019 and December 2023. Patients underwent regular evaluations, including clinical, functional, and microbiological assessments, alongside completion of quality of life, anxiety, and depression questionnaires. We evaluated whether there was a difference in anxiety and depression levels over time. Results. After 12 months of treatment, significant improvements were noted in body mass index (BMI), lung function (FEV1 %), sweat test (ST) and various aspects of quality of life (CFQ-R). However, anxiety and depression levels did not differ significantly during the follow-up. When we stratified our sample by key groups, we observed that younger patients (under 28 years) and those with homozygous Phe508del mutations experienced significant higher anxiety with no differences on depression. Furthermore, anxiety and depression demonstrated a moderate correlation, strengthening over time. Conclusions. Treatment with ETI establishes significant improvements in lung function, BMI, sweat test and quality of life in patients with CF. However, despite these positive outcomes, there were no significant changes observed in levels of anxiety and depression, except for individuals with homozygous mutation type and those younger than 28 years old, who exhibited significant higher levels of anxiety.

Ivacaftor

Depression

10.21203/rs.3.rs-4754430/v1

Cite

Citations (0)

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients

BMC Pulmonary Medicine (2025)

Marta Solís García Adrián Peláez Rosa Mar Gómez-Punter M. López Claudia Madrid Carbajal

Abstract Background This study aimed to assess how Elexacaftor/Tezacaftor/Ivacaftor (ETI) influences lung function, Body Mass Index (BMI), Sweat Test (ST) and mental health of Cystic Fibrosis (CF) patients, emphasizing on depression and anxiety. Methods We conducted an observational, prospective, multicentre study including 108 patients over 18 years old who initiated ETI therapy between December 2019 and December 2023. Patients underwent regular evaluations, including clinical, functional, and microbiological assessments, alongside completion of quality of life, anxiety, and depression questionnaires. We evaluated whether there was a difference in anxiety and depression levels over time. Results After 12 months of treatment, significant improvements were noted in BMI, lung function (FEV1%), ST and various aspects of quality of life (CFQ-R). However, anxiety and depression levels did not differ significantly during the follow-up. When we stratified our sample by key groups, we observed that younger patients (under 28 years) and those with homozygous Phe508del mutations experienced significant higher anxiety with no differences on depression. Furthermore, anxiety and depression demonstrated a moderate correlation, strengthening over time. Conclusions Treatment with ETI establishes significant improvements in lung function, BMI, ST and quality of life in patients with CF. However, despite these positive outcomes, there were no significant changes observed in levels of anxiety and depression, except for individuals with homozygous mutation type and those younger than 28 years old, who exhibited significant higher levels of anxiety.

Depression

Ivacaftor

10.1186/s12890-024-03455-2

Cite

Citations (0)

ABO blood group as a determinant of COVID-19 and Long COVID: An observational, longitudinal, large study

PLoS ONE (2023)

Joan B. Soriano Adrián Peláez Xavier Busquets María Rodrigo-García Elena Ávalos

Background An association of ABO blood group and COVID-19 remains controversial. Methods Following STROBE guidance for observational research, we explored the distribution of ABO blood group in patients hospitalized for acute COVID-19 and in those with Long COVID. Contingency tables were made and risk factors were explored using crude and adjusted Mantle-Haentzel odds ratios (OR and 95% CI). Results Up to September 2022, there were a total of 5,832 acute COVID-19 hospitalizations in our hospital, corresponding to 5,503 individual patients, of whom blood group determination was available for 1,513 (27.5%). Their distribution by ABO was: 653 (43.2%) group 0, 690 (45.6%) A, 113 (7.5%) B, and 57 (3.8%) AB, which corresponds to the expected frequencies in the general population. In parallel, of 676 patients with Long COVID, blood group determination was available for 135 (20.0%). Their distribution was: 60 (44.4%) from group 0, 61 (45.2%) A, 9 (6.7%) B, and 5 (3.7%) AB. The distribution of the ABO system of Long COVID patients did not show significant differences with respect to that of the total group (p ≥ 0.843). In a multivariate analysis adjusting for age, sex, ethnicity, and severity of acute COVID-19 infection, subgroups A, AB, and B were not significantly associated with developing Long COVID with an OR of 1.015 [0.669–1.541], 1.327 [0.490–3.594] and 0.965 [0.453–2.058], respectively. The effect of the Rh+ factor was also not significant 1,423 [0.772–2,622] regarding Long COVID. Conclusions No association of any ABO blood subgroup with COVID-19 or developing Long COVID was identified.

10.1371/journal.pone.0286769

Cite

Citations (4)

Trends in mortality in Spain, with a special focus on respiratory-related conditions in the midst of the COVID-19 pandemic

Medicina Clínica (English Edition) (2025)

Adrián Peláez Joan B. Soriano María Rodrigo-García José L. Peñalvo Julio Ancochea

Pandemic

2019-20 coronavirus outbreak

10.1016/j.medcle.2024.08.005

Cite

Citations (0)

Understanding COPD underdiagnosis in the post-COVID era

05.02 - Monitoring airway disease (2023)

Elena Ávalos María Rodrigo-García Adrián Peláez Laura Castellanos López Alberto Martínez De Lara

Introduction: COPD underdiagnosis remains a global concern, reaching 74.7% in Spain according to EPISCAN II. The COVID-19 pandemic collapsed many pneumology services from 2020 and onwards. We aimed to characterize COPD within our post-COVID follow-up and explore its underdiagnosis. Methods: We evaluated patients seen in our post-COVID follow-up between April 2020 and December 2022, and performed a descriptive analysis of their clinical and functional variables. We compared those with or without a previous diagnosis of COPD according to clinical history, and their most recent spirometry, defining COPD as a postBD FEV1/FVC<0.7). Results: From 473 patients, 287 (60.8%) were men and 186 (39.2%) were women with a mean±SD age of 65.3±13.2 and 65.3±14.6 yrs., respectively. Out of the total, 420 (88.8%) patients performed spirometry during follow-up. From those 420 patients, 31 (7.4%) had previous diagnosis of COPD according to clinical history, while 48 (11.4%) had COPD by spirometric criteria. Correct COPD diagnosis was 33.3%, underdiagnosis 66.6%, and overdiagnosis 4.0%. By gender, COPD underdiagnosis was 58.3% in women and 69.4% in men (p>0.05). We found significant differences (p<0.05) between COPD sub-populations (under-, over- and well- diagnosed), in the number of comorbidities (lower in underdiagnosed patients), and their characteristics (underdiagnosed had less smoking habit and lower pack-year index, among others). Conclusion: In our post-COVID follow-up 11.2% of patients were incorrectly diagnosed of COPD (either over- or underdiagnosed). Underdiagnosed patients had less comorbidities and less smoking. More comprehensive screening and diagnostic protocols for COPD are still needed, especially during the post-COVID era.

Overdiagnosis

Pulmonology

Smoking history

10.1183/13993003.congress-2023.pa2400

Cite

Citations (0)